Fibroblasts as novel therapeutic targets in chronic inflammation

被引：141

作者：

Flavell, S. J. ^{[1
]}

Hou, T. Z. ^{[1
]}

Lax, S. ^{[1
]}

Filer, A. D. ^{[1
]}

Salmon, M. ^{[1
]}

Buckley, C. D. ^{[1
]}

机构：

[1] Univ Birmingham, MRC Ctr Immune Regulat, Rheumatol Res Grp, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2008年 / 153卷

基金：

英国医学研究理事会;

关键词：

inflammation; fibroblasts; cancer; therapy;

D O I：

10.1038/sj.bjp.0707487

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A characteristic feature of many chronic inflammatory diseases is their persistence and predilection for certain sites. The molecular basis for such tissue tropism and failure of the inflammatory response to resolve has until relative recently remained obscure. Recent studies have strongly implicated fibroblasts as cells which contribute to disease persistence and which help define anatomical location. Therefore fibroblasts make an attractive therapeutic target as they help orchestrate the inflammatory infiltrate. Current anti-inflammatory therapies target immune cells in an attempt to inhibit the production of pro-inflammatory mediators. However an equally important target is the active induction of pro-resolution programmes responsible for the resolution of inflammation. Fibroblasts are likely to be an important source of these anti-inflammatory mediators. Therapeutic manipulation of fibroblasts and their biologically active products is an emerging concept in treating cancer and is likely to provide a novel method to achieve improved control of chronic inflammatory disease.

引用

页码：S241 / S246

页数：6

共 52 条

[1] Lymphostromal interactions in thymic development and function [J].